Organon is selling its JADA post-partum haemorrhage (PPH) treatment system to Laborie Medical in a deal valued at up to $465m. The US-based company will receive $440m at the deal’s closing, with ...
The JADA ® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. Avoid excessive force when inserting ...
The JADA System is a medical device that uses low-level intrauterine vacuum to control and treat abnormal postpartum uterine bleeding or hemorrhage. Since acquiring the device in June 2021, Organon ...
Organon & Co. OGN announced the completion of the divestiture of its JADA System to Laborie Medical Technologies Corp. The deal is worth up to $465 million, including $440 million paid at closing and ...
The Jada System is comprised of an intrauterine device that utilizes low level vacuum to induce normal contraction of the uterus. The Food and Drug Administration has cleared updates to the Jada ® ...
The JADA ® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. Organon (NYSE: OGN) is a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results